For the year ending 2025-12-31, ABCL has $1,356,950K in assets. $390,046K in debts. $128,513K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 128,513 | |||
| Marketable securities | 405,313 | |||
| Total cash, cash equivalents, and marketable securities | 533,826 | |||
| Accounts and accrued receivable | 58,293 | |||
| Restricted cash | 25,000 | |||
| Other current assets | 111,113 | |||
| Total current assets | 728,232 | |||
| Property and equipment, net | 428,003 | |||
| Gross carrying amount | 69,320 | |||
| Accumulated amortization | 30,939 | |||
| Intangible assets, net | 38,381 | |||
| Goodwill | 47,806 | |||
| Investments in equity accounted investees | 62,580 | |||
| Other long-term assets | 51,948 | |||
| Total long-term assets | 628,718 | |||
| Total assets | 1,356,950 | |||
| Accounts payable and other current liabilities | 50,781 | |||
| Contingent consideration payable | 0 | |||
| Deferred revenue | 13,526 | |||
| Total current liabilities | 64,307 | |||
| Operating lease liability | 137,403 | |||
| Deferred government contributions | 174,453 | |||
| Deferred tax liability | 9,115 | |||
| Other long-term liabilities | 4,768 | |||
| Total long-term liabilities | 325,739 | |||
| Total liabilities | 390,046 | |||
| Common shares no par value, unlimited authorized shares at december31, 2024 and december31, 2025 295,757,002 and 300,600,710 shares issued and outstanding at december31, 2024 and december31, 2025, respectively | 802,341 | |||
| Additional paid-in capital | 198,279 | |||
| Accumulated other comprehensive loss | -4,234 | |||
| Accumulated earnings (deficit) | -29,482 | |||
| Total shareholders' equity | 966,904 | |||
| Total liabilities and shareholders' equity | 1,356,950 | |||
AbCellera Biologics Inc. (ABCL)
AbCellera Biologics Inc. (ABCL)